Our research expertise spans cancer genomics, DNA damage, RNA biology, and drug development. We are also expanding our focus on drug delivery, particularly through nanotechnology-based methods for delivering small RNA mimics and inhibitors.
News
- Clinical Cancer Research: Preclinical Activity of the B7-H3-Targeting Antibody Drug Conjugate (ADC) Vobramitamab Duocarmazine (Vobra Duo) in Pediatric Cancer Solid Tumors (Chen, Houghton, Kurmasheva Lab)
- Ubiquitylation of DNA polymerase β via atypical K27 chains signals a DNA damage response (Sung Lab)
- David Libich, PhD Awarded Five‑Year, $2.1 million NIH Grant to Study “Protein Intrinsic Disorder in Genome Regulation.”
- Journal of Biological Chemistry: Structural Basis for the Mechanism and Stability of the EEPD1 5’ Endonuclease (Gupta Lab)
- Graduate School of Biomedical Sciences (GSBS) Outstanding Student Awards
Events
Greehey CCRI Seminar Series: Wenshe Ray Liu, PhD (TX A&M)
Presentation title: “Targeting YEATS – An Epigenetic Reader Domain for Anti-Cancer Drug Discovery.”
5th Annual Gear Up Against Kids Cancer Bike Ride
Signing up for the 5th Annual Gear Up Against Kids Cancer bike ride is a powerful way to support local childhood cancer research and turn your passion for cycling into a meaningful impact. Every dollar you raise helps fund essential research projects at the Greehey Children’s Cancer Research Institute – UT Health San Antonio, driving innovative studies and treatments that benefit children in our community fighting cancer.